The Effect of Berberine Chloride on Experimental Colitis in Rats In Vivo and In Vitro

HAIYAN ZHOU and SATORU MINESHITA

Department of Preventive Medicine, Division of Social Medicine, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

Accepted for publication May 15, 2000 This paper is available online at http://www.jpet.org

ABSTRACT

Berberine is an isoquinoline alkaloid with multiple pharmacological actions, including anti-inflammatory activity. The aims of this study were to examine the effect of berberine on the mucosal healing process and to investigate whether berberine can inhibit the increased production of interleukin-8 in trinitrobenzene sulfonic acid-induced colitis in rats. Berberine was administered orally for 3 days or 1 week at a dosage of 7.5 or 15 mg/kg/day. Tissue damage scores, body weight, colon wet weight, and colon wall thickness were measured, and myeloperoxidase activity in colon tissue was also examined. Histological lesions, morphological damage, and myeloperoxidase activity were reduced after 1 week of treatment with berberine at a dosage of 15 mg/kg/day. Furthermore, 1 week after trinitrobenzene sulfonic acid treatment, the production of interleukin-8 by cultured rectal mucosa or cardiac blood mononuclear cells with or without stimulation of lipopolysaccharide for 24 h was also analyzed by enzyme-linked immunosorbent assay. Cardiac blood mononuclear cells and rectal mucosa of normal rats produced substantial amounts of interleukin-8, which increased strikingly with the stimulation of lipopolysaccharide. Cardiac blood mononuclear cells and rectal mucosa of trinitrobenzene sulfonic acid-treated rats secreted more interleukin-8 than those of normal rats. The addition of berberine with a concentration of $10^{-5}$ M to the culture media resulted in an inhibition of interleukin-8 production of rectal mucosa.

Berberine is the major alkaloid distributed in Goldenseal (Hydrastis canadensis) (Jang, 1941), which is a popular herb in the United States. In Chinese medicine, Coptidis rhizoma and Phellodendri cortex have been used to treat the patients who have gastroenteritis, abdominal pain, or diarrhea. Berberine was also identified as a major component in those plants and proved to have biological activities, such as bacteriocidal activity, an anticholera toxin effect, and an anti-inflammatory effect. Its structural formula is shown in Fig. 1. In this study, we characterized the effect of berberine on trinitrobenzene sulfonic acid (TNB)-induced colitis in rats in vivo and in vitro.

The pathological features of inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis, are marked by the presence of mucosal ulceration and the infiltration of neutrophils and lymphocytes in the mucous membranes. Although immunologic mechanisms have been postulated to play an important role in the pathogenesis of these diseases, the etiology remains obscure. The mainstream of medical therapy focuses on inhibition of the effect of the inflammatory mediators operant in IBD because the causes of these two chronic disorders are unknown. To investigate the etiology of IBD and the effects of drugs on tissue damage, animal models have been reported as useful. In particular, TNB-induced colitis has been suggested as the more relevant model of IBD because this model involves the use of an immunologic hapten that results in acute inflammation with ulcers that evolves into chronic inflammation of the distal colon (Morris et al., 1989). Glucocorticoid and salicylazosulfapyridine have been mainly used for the treatment of these diseases, but their side effects remain a major clinical problem. Consequently, traditional Chinese herbal medicine has recently generated increasing interest for the treatment of these disorders. We have reported the beneficial effects of traditional Chinese medicine on refractory steroid-dependent and steroid-resistant ulcerative colitis in human (Zhou et al., 1995) and the beneficial effects of Oren-gedoku-to (a complex mixture of ingredients derived from C. rhizoma, Scutellariae radix, P. cortex, and Gardeniae fructus plants) on TNB-induced colitis in rats (Zhou and Mineshita, 1999a). Although the precise mechanism of action for Oren-gedoku-to and the whole constituents of Oren-gedoku-to are still unclear; berberine, the main constituent of C. rhizoma and Phellodendri cortex, may play an important role on the mucosal healing process and reduction of interleukin-8 (IL-8). The enhanced production of potent inflammatory cytokine IL-8 in IBD has

ABBREVIATIONS: TNB, trinitrobenzene sulfonic acid; IBD, inflammatory bowel disease; MPO, myeloperoxidase; LPS, lipopolysaccharide; CBMC, cardiac blood mononuclear cell; IL, interleukin.

Received for publication March 6, 2000.
been studied (Nielsen et al., 1987; Daig et al., 1996). In experimental studies, it has also been demonstrated that berberine inhibits cyclooxygenase-2 transcriptional activity (Fukuda et al., 1999) and lipoxygenase activity (Misik et al., 1995).

The aims of this study were to investigate the production of IL-8 in normal and inflamed rat colon and to evaluate the effect of berberine on IL-8 production by cultured rectal mucosa or cardiac blood mononuclear cells obtained from rats with colitis induced by TNB in vitro. Furthermore, we examined the ability of berberine to modify the course of mucosal changes in TNB-induced colitis in rats.

Materials and Methods

Animals

Male Sprague-Dawley rats (180–220 g), obtained from Saitama Animal Laboratories (Saitama Prefecture, Japan), were used. They were kept in a restricted-access room with a controlled temperature (22°C ± 2°C) and light/dark cycle (12/12 h). Three animals were housed in each standard wire mesh cage, and they were fed standard pellets withtap water freely available. All of the animal studies adhered to the guidelines established by the Tokyo Medical and Dental University for the care and use of laboratory animals.

In Vivo Experiment

Colitis Induction. Experimental colitis was induced using TNB as described by Morris et al. (1989). In brief, rats that had been fasted for 16 h were lightly anesthetized with pentobarbital sodium (20 mg/kg i.p.), and then 0.25 ml of 50% ethanol containing 30 mg TNB was infused intrarectally via a catheter. The tip of the catheter was inserted after removing distal stools so it was set at 7 cm proximally to the anus. To clear the TNB/ethanol solution from the catheter, 0.5 ml of air was injected, and then the rats were left for 5 min in a supine Trendelenburg position with the anus clipped. Tissue paper was laid in the cages and changed twice a day to minimize the pain and distress of the rats due to diarrhea after TNB treatment for 1 week. The control group of rats were also subjected to the same surgical procedures as described, but they were injected with normal saline instead of TNB.

Experimental Design. TNB/ethanol colitis was induced in 30 rats, which were then randomized into three groups to receive a daily oral administration of berberine (7.5 mg/kg, n = 10; 15 mg/kg, n = 10) or an equal volume of distilled water (n = 10) from day 1 for 1 week. In addition, an additional 10 rats, which were used as control animals, received an injection of saline instead of TNB, and distilled water was given from day 1 for 1 week. Observations were made at 3 days and 1 week after the intrarectal administration of TNB. The rats were euthanized by pentobarbital sodium (90 mg/kg i.p.), and a 10-cm segment of the distal colon was removed for the biochemical and morphological studies.

Body Weight Measurement. The rats were weighed between 9:00 and 10:00 AM on an electric balance every day before and after the TNB treatments for 1 week.

Macroscopic Assessment of Colonic Damage. On the 3rd day and 1 week after the intrarectal administration of 30 mg of TNB in 50% ethanol, five rats from each group were randomly selected and euthanized by pentobarbital sodium (90 mg/kg i.p.). The distal colons were removed, opened by longitudinal incisions, and assigned code numbers. Each colon was assessed by a semiquantitative scoring system, as described previously (Vilaseca et al., 1990), in a blind trial procedure. Table 1 shows the macroscopic and microscopic scoring system that was used.

Histological Evaluation of Colonic Damage. After macroscopic scoring, the mass of colon (7 cm from the anus) was taken out and weighed at once. Then two tissue samples (2 × 10 mm) were excised from the central part of the lesion of each colon. When there was no inflammation macroscopically, at least one sample was taken. The tissue samples were fixed in 4% buffered formaldehyde and prepared for routine paraffin embedding. Sections of tissue were cut into 5-μm slices on a microtome, mounted onto slides, and then stained with H&E. Histological assessment by light microscopy was performed in a blind method on coded slides using the criteria of Vilaseca et al. (1990) as outlined in Table 1. As an index of tissue edema, the thickness of the colonic wall was determined by measuring the distance from the serosal surface to the luminal surface of the mucosa. The diameter of the mucosal and muscularis propria were separately measured.

<table>
<thead>
<tr>
<th>Criteria for assessment of colonic damage</th>
<th>Macroscopic Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adhesions</td>
<td>None 0, Minimal 1</td>
</tr>
<tr>
<td>Involving several bowel loops</td>
<td>2</td>
</tr>
<tr>
<td>Structures</td>
<td>None 0, Mild 2, Severe, proximal dilatation 3</td>
</tr>
<tr>
<td>Ulcers</td>
<td>None 0, Linear ulceration &lt;1 cm 1, Two linear ulcers &lt;1 cm 2, More sites of ulceration or one large ulcer &gt;1 cm 3</td>
</tr>
<tr>
<td>Wall thickness</td>
<td>Less than 1 mm 0, 1–3 mm 1, More than 3 mm 2</td>
</tr>
<tr>
<td>Maximum score</td>
<td>10</td>
</tr>
</tbody>
</table>

Microscopic Score

<table>
<thead>
<tr>
<th>Ulceration</th>
<th>Microscopic Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No ulcer, epithelisation</td>
<td>0</td>
</tr>
<tr>
<td>Small ulcers &lt;3 mm</td>
<td>1</td>
</tr>
<tr>
<td>Large ulcers &gt;3 mm</td>
<td>2</td>
</tr>
<tr>
<td>Inflammation</td>
<td>None 0, Mild 1, Moderate 2, Severe 3</td>
</tr>
<tr>
<td>Depth of the lesion</td>
<td>None 0, Submucosa 1, Muscularis propria 2, Serosa 3</td>
</tr>
<tr>
<td>Maximum score</td>
<td>8</td>
</tr>
</tbody>
</table>

The criteria of Vilaseca et al. (1984) was modified from a maximum score of 10 to that of 8, which has no fibrogenesis involved, because there was no fibrogenesis showing at 1 week after the colitis. Furthermore, the inflammation was evaluated by infiltration of inflammatory cells on a scale of 0 to 3, which was described by Zipser et al. (1987).
evaluated for infiltration of inflammatory cells, such as neutrophils, eosinophils, macrophages, and lymphocytes. A scale of 0 to 3 was used to semiquantify inflammatory cell infiltration: 0, 0 to 10 leukocytes per high-power field (HPF); 1, 11 to 25 leukocytes/HPF; 2, 26 to 50 leukocytes/HPF; and 3, ≥51 leukocytes/HPF. At least 8 HPFs from each section were examined (Zipser et al., 1987).

Myeloperoxidase (MPO) Activity Measurement. MPO is an enzyme that is found predominantly in the azurophilic granules of neutrophils and has been used as a quantitative index of inflammation in several tissues, including the intestine (Krawisz et al., 1984). Samples of colon were obtained from the most inflamed part of lesion after the samples for histological examination were derived. Samples were immediately washed in cold PBS, pH 7.4, and blotted to remove the interfering blood and dirt. Subsequent to weighing on an analytical balance, the distal segment of the colon (150–300 mg) was suspended in 1.0 ml of ice-cold 0.5% hexadecyltrimethylammonium bromide in 50 mM phosphate buffer, pH 6.0, and then homogenized three times for 30 s using a tissue homogenizer (OMNI GLH-2017; Yamato Scientific Co., Ltd., Tokyo, Japan). The probe was rinsed twice with 1.0 ml of the buffer. After the homogenate thawed and froze three times, it was centrifuged for 15 min at 12,000 g. The tissue level of MPO activity was measured spectrophotometrically: 0.1 ml of supernatant was combined with 2.4 ml of 60 mM phosphate buffer, pH 6.0, containing 0.2 mg/ml O-dianisidine hydrochloride. After preincubation for 10 min at 25°C, 0.5 ml of 0.003% hydrogen peroxide was added to the buffer; after incubation for an additional 10 min, 0.5 ml of 0.1% sodium azide was added to stop the reactions. The absorbance at 460 nm was measured on a spectrophotometer (DU-640; Beckman Instruments, Inc., Fullerton, CA). A unit of MPO activity was defined as that converting 1 μmol of hydrogen peroxide to water in 1 min at 25°C and was divided by colonic wet weight. The MPO assay was performed in a blind fashion on coded tubes.

In Vitro Experiment

Experimental Design. Cardiac blood mononuclear cells (CBMCs) and rectal mucosa were obtained from six normal rats and six rats with TNB-induced colitis. The cells and rectal mucosa were cultured with or without stimulation of lipopolysaccharide (LPS) derived from the Escherichia coli strain 0111:B4 for 24 h. Berberine at a concentration of 10^{-6} or 10^{-5} M was added to the culture medium, which was stimulated by LPS. IL-8 levels in the medium were measured by enzyme-linked immunosorbent assay method using a commercial kit.

CBMC Culture. One week after TNB administration, six rats with TNB-induced colitis and six normal rats (control group) were euthanized with pentobarbital sodium (90 mg/kg i.p.). CBMCs were separated as previously described by Boyum (1968) using Ficoll-Paque solution. Cardiac blood diluted with balanced salt solution (1:1) containing 100 I.U. heparin/ml was layered over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) and centrifuged for 40 min at 400 g. Cells harvested from the interface were washed three times in Ca^{2+}- and Mg^{2+}-free PBS and resuspended at a final concentration of 2 × 10^6/ml in a culture medium consisting of RPMI 1640 supplemented by 10% heat-inactivated FBS, 2 mM L-glutamine, 100 I.U./ml penicillin, and 100 μg/ml streptomycin. Thereafter, the rat CBMCs were incubated with doses of berberine ranging from 10^{-6} to 10^{-5} M, with or without simultaneous activation by 100 μg/ml LPS in 24-well culture plates (Falcon; Polylabo, Strasbourg, France) for 24 h at 37°C in a humidified 5% CO_2, 95% air atmosphere. Supernatants were then removed, filtered (0.45 μm), and stored at −80°C until IL-8 measurement. The cell viability was assessed by the trypan blue exclusion test (Phillips, 1973).

Intestinal Specimens and Tissue Culture. One week after TNB administration, rats were euthanized as described before. Rectal mucosal specimens were scraped from the marked inflamed part, avoiding ulcerative areas, and placed in Ca^{2+}- and Mg^{2+}-free PBS supplemented with 100 I.U./ml penicillin and 100 μg/ml streptomycin at 4°C for organ culture. After collection, the tissue was gently
washed three times in PBS with added penicillin and streptomycin, blotted carefully, weighed (22–25 mg), and placed in 24-well tissue culture plates in 1 ml of RPMI 1640 culture medium with or without simultaneous activation by 100 μg/ml LPS. Berberine (10⁻⁶ to 10⁻⁵ M) was also added into the culture medium, which was exposed to LPS. After 24 h in culture at 37°C in a humidified 5% CO₂, 95% air atmosphere, supernatants were removed, filtered (0.45 μm), and stored at −80°C until IL-8 measurement.

**Measurement of IL-8 Production in Culture Medium.** Culture supernatants were diluted 1:2 to 1:30 in assay buffer, and IL-8 levels were quantified with a commercially available rat IL-8 enzyme-linked immunosorbent assay system (Amersham Pharmacia Biotech UK Limited, Amersham, England) according to the manufacturer's instructions. The detection limit of this assay was 4.7 pg/ml. The absorbance at 450 nm was measured on a 96-well plate reader. The levels of IL-8 in culture medium were expressed as picograms of immunoreactive IL-8 per milliliter of medium.

**Chemicals and Reagents**

For the in vivo experiment, berberine chloride (purity of 99.0%; Sigma Chemical Co., St. Louis, MO) was suspended in distilled water and shaken for 30 min. For the in vitro experiment, berberine chloride (purity of 99.0%; Wako Pure Chemical Industries, Ltd., Osaka, Japan) was suspended in culture medium that adjusted the concentration to 10⁻⁶ and 10⁻⁵ M.

TNB was also obtained commercially from Sigma Chemical Co. It was dissolved in 50% ethanol and shaken for 30 min before use. LPS from *E. coli* 0111:B4 was obtained commercially from Wako Pure Chemical Industries, Ltd. It was dissolved in distilled water and adjusted to the concentration of 100 μg/ml before use.

Hexadecyltrimethylammonium bromide and hydrogen peroxide for MPO activity measurement were obtained commercially from Wako Pure Chemical Industries, Ltd. O-Dianisidine hydrochloride was obtained commercially from Sigma Chemical Co.

For cell and organ culture, RPMI 1640, L-glutamine, fetal beef serum (FBS), and trypan blue were obtained commercially from GIBCO BRL, Life Technologies (Grand Island, NY). Penicillin and streptomycin were obtained commercially from Sigma Chemical Co.

**Statistical Analysis**

All values are expressed as mean ± S.D. The Student’s t test and Mann-Whitney U test were used for parametric and nonparametric statistical evaluation, respectively. A value of *P* < .05 was considered as the level of significance.

**Results**

**General Observations**

Intrarectal administration of TNB/ethanol resulted in an inflammatory response characterized by extensive mucosal...
disruption, linear and deep ulcers, hemorrhage, and submucosal edema. The adhesions between colon and small bowel and other organs were seen in 90% of the rats. Diarrhea and lack of weight gain were seen in all rats without berberine treatment.

**In Vivo Experiment**

**Effect of Berberine on Body Weight.** The effect of berberine on body weight change is shown in Fig. 2. Body weight is expressed as the percentage of weight on the day before TNB treatment. The body weight of rats treated with 30 mg of TNB decreased throughout the 5-day post-treatment period and increased slightly on the 7th day. The group given berberine (15 mg/kg) for 1 week showed quicker recovery of their body weight. However, there were no differences between the two groups treated with berberine at the 3rd day and between the group treated with a low dose of berberine at the 7th day and the TNB control group.

**Effect of Berberine on Macroscopic Damage.** Figure 3A shows the macroscopic scores obtained from rats euthanized 3 days and 1 week after the TNB (30 mg) administration. At 1 week, the mean macroscopic damage scores were lower in those rats that had been treated with berberine (15 mg/kg) than in the TNB control group, but there were no significant differences among the other groups. Figure 4 shows the macroscopic views of the colons that were obtained from TNB control and berberine-treated rats euthanized at various times later. The development of chronic inflammatory lesions in the colon was mitigated by the berberine at a dosage of 15 mg/kg for 1 week. However, there were no differences in the...
Effects of Berberine on Histological Damage Score.

The histological appearance of tissues examined at 3 days and 1 week after the administration of TNB (30 mg) showed tissue damage characterized by edema, hemorrhage, epithelial exfoliation, and infiltration of polymorphonuclear leukocytes, macrophages, eosinophils, and lymphocytes. There was more inflammatory cell infiltration at 1 week after TNB administration than that of the 3rd day. As shown in Fig. 3B, the mean histological damage score of the distal colon was lower at 1 week in the group given berberine (15 mg/kg), but there were no significant differences between the two berberine groups at the 3rd day and between the group given low-dose berberine at 1 week and the TNB control group. Figure 5 shows the histological sections of the intestines obtained from the TNB control and berberine-treated rats at 1 week.

Effects of Berberine on Wet Weight and Wall Thickness of Colon. Table 2 shows the mean wet weight of distal colons (7 cm) and the mean intestinal wall thickness at the site of grossly visible ulceration and inflammation at 3 days and 1 week after the colitis was induced by 30 mg of TNB. Wet weight and wall thickness of the colon were decreased at 1 week in the group given berberine (15 mg/kg) compared with the control group. However, there were no differences between the two berberine groups at the 3rd day and between the low-dose berberine group at 1 week and the TNB control group.

Effect of Berberine on Ulceration of Colon. The ulceration of colon was examined at 3 days and 1 week after the colitis was induced by 30 mg of TNB. As shown in Table 3, the mean diameter of the colonic ulcers was smaller at 1 week in the group given berberine (15 mg/kg) than in the control group, but there were no significant differences between the two berberine groups at the 3rd day and between the low-dose berberine group at 1 week and the TNB control group.

Discussion

In the present study, the administration of berberine markedly reduced the inflammation in rats with TNB-induced colitis, as verified by effects on macroscopic and histological damage scores. Berberine chloride (15 mg/kg) significantly decreased the wet weight of colon and intestinal wall thickening on day 7 compared with TNB (30 mg) group.

### Table 2
Effect of berberine chloride on wet weight of colon and intestinal wall thickness

<table>
<thead>
<tr>
<th>Time</th>
<th>Normal</th>
<th>TNB Only</th>
<th>Berberine Chloride (7.5 mg/kg)</th>
<th>Berberine Chloride (15 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/cm</td>
<td>mm</td>
<td>mg/cm</td>
<td>mm</td>
</tr>
<tr>
<td>Day 3</td>
<td>629.6 ± 63.1</td>
<td>1934.4 ± 174.3</td>
<td>1834.2 ± 159.6</td>
<td>1816.7 ± 183.3</td>
</tr>
<tr>
<td>Day 7</td>
<td>627.5 ± 60.6</td>
<td>1980.4 ± 86.2</td>
<td>1934.3 ± 159.5</td>
<td>1323.6 ± 149.0</td>
</tr>
</tbody>
</table>

* P < .001, significant difference from normal rats.

### Table 3
Effect of berberine chloride on intestinal ulceration

<table>
<thead>
<tr>
<th>Time after Treatment</th>
<th>TNB Only</th>
<th>TNB + Berberine Chloride (7.5 mg/kg)</th>
<th>TNB + Berberine Chloride (15 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mm</td>
<td>mm</td>
<td>mm</td>
</tr>
<tr>
<td>Day 3</td>
<td>3.4 ± 0.6</td>
<td>2.9 ± 0.5</td>
<td>3.1 ± 0.5</td>
</tr>
<tr>
<td>Day 7</td>
<td>3.8 ± 0.9</td>
<td>3.2 ± 0.6</td>
<td>2.5 ± 0.5</td>
</tr>
</tbody>
</table>

* P < .05, significant difference from TNB control group.

### Table 4
Effect of berberine chloride on MPO activity of intestinal wet tissue

<table>
<thead>
<tr>
<th>Time after Treatment</th>
<th>Normal</th>
<th>TNB Only</th>
<th>TNB + Berberine Chloride (7.5 mg/kg)</th>
<th>TNB + Berberine Chloride (15 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>U/100 mg wet tissue</td>
<td>U/100 mg wet tissue</td>
<td>U/100 mg wet tissue</td>
<td>U/100 mg wet tissue</td>
</tr>
<tr>
<td>Day 3</td>
<td>0.5 ± 0.1</td>
<td>3.2 ± 0.8</td>
<td>2.6 ± 0.9</td>
<td>2.4 ± 1.1</td>
</tr>
<tr>
<td>Day 7</td>
<td>0.6 ± 0.1</td>
<td>3.5 ± 1.3</td>
<td>2.3 ± 1.3</td>
<td>1.7 ± 0.7</td>
</tr>
</tbody>
</table>

* P < .001, significant difference from normal rats.

* P < .05, significant difference from TNB control group.
logical damage and MPO activity. The IL-8 production in cultured mucosa of inflamed colon was increased compared with noninflamed colon. The addition of berberine with a concentration of $10^{-5}$ M to the culture medium inhibited the IL-8 production in response to LPS in vitro. This suggests that the inhibitory effect of berberine on colonic IL-8 production may contribute to the tissue healing process, although a direct cause-and-effect relationship must be proved.

Our results showed a beneficial effect of berberine on the inflammatory response in TNB-induced colitis in rats in vivo. One week of treatment with berberine reduced the colonic mucosal inflammation as demonstrated by macroscopic and histological examination, analysis on colonic wet weight, and MPO activity. This is in agreement with our previous findings that showed similar anti-inflammatory effects of Oren-gedoku-to on TNB-induced colitis in rats (Zhou and Mineshita, 1999a). Oren-gedoku-to is a traditional Chinese herbal medicine that consists of a mixture of C. rhizoma, S. radix, P. cortex, and G. fructus. Although the entire composition of each of these herbal medicines is not yet completely known, the investigations of the chemical compositions and immunological properties show that their activities are mainly due to the major alkaloid berberine in C. rhizoma and P. cortex, baicalein and baicalein in S. radix, and geniposide in G. fructus. We have previously reported that baicalein inhibits IL-8 production of cultured blood mononuclear cells and rectal mucosa (Zhou and Mineshita, 1999b), and our unpublished data have shown that geniposide has no effect on TNB-induced colitis at an oral administration of 10 to 20 mg/kg/day for 1 week. However, the mechanism of the anti-inflammatory actions of Oren-gedoku-to seems to be more complex. Our results in the present study showed that the major constituent of berberine may play an important role in attenuating the inflammation induced by TNB.

It has been suggested that increased intestinal permeability is a primary etiologic factor in both IBD (Stein et al., 1998) and TNB-induced colitis (Yamada et al., 1992). Furthermore, alterations in active electrolyte transport by the diseased epithelium would result in altered water flux and could thereby contribute to the secretory diarrhea that is a frequent symptom of IBD. It has also been reported that berberine inhibits ion transport in human colonic epithelia and decreases the intestinal permeability (Taylor et al., 1999). Those previous reports can help us to explain in part the effect of berberine on TNB-induced colitis.

IL-8 is an important cytokine for the recruitment and activation of polymorphonuclear neutrophils cells that are abundant in the intestinal lesions of IBD. It has been previously reported that locally generated IL-8 is involved in neutrophil migration and binding to extracellular matrix (Ina et al., 1997). Increased mucosal generation of IL-8 may attract neutrophils from the circulation into the inflammatory site and induce binding of neutrophils in the interstitial tissue, contributing to the accumulation and activation of neutrophils in the affected mucosa with IBD. A large number of studies have shown increased levels of IL-8 in ulcerative colitis and Crohn’s disease (Izzo et al., 1992, 1993; Mitsuyama et al., 1994; Izutani et al., 1995; Daig et al., 1996). Therefore, the inhibition of the IL-8 production is believed to provide a novel approach to the treatment of IBD.

Berberine is an isoquinoline alkaloid present in numerous plants of the genera Berberis and Coptis. It has a wide range of pharmacological and biological activity, including anti-inflammatory and antimicrobial properties. The anti-inflammatory and immunosuppressive activity of berberine is well established by previous investigators (Akhter et al., 1977; Li et al., 1989; Teh et al., 1990; Kondo et al., 1992; Seow et al., 1992; Ivanovska and Philipov, 1996). Therefore, berberine has been used in traditional Eastern medicine for more than 2 millennia in the treatment of bacterial or secretory diarrhea and gastroenteritis (Lahiri and Dutta, 1967; Tang and Eisenbrand, 1992). Its therapeutic benefits have been attributed in part to antimicrobial (Iwasa et al., 1998) and antisecretory (Tui et al., 1981; Taylor et al., 1999) actions. In addition, the inhibitory effect of berberine on cyclooxygenase-2 has been demonstrated (Fukutake et al., 1998; Fukuda et al., 1999). Miura et al. (1997) reported the inhibitory action of berberine on apoptosis; and Ckless et al. (1995) reported the inhibition of in vitro lymphocyte transformation by berberine. The lipoxygenase inhibition and antioxidant properties of berberine have also been reported by Misik et al. (1995). However, the effect of berberine on IL-8 in IBD has not yet been reported. In the present study, we have shown the beneficial effect of berberine on the mucosa healing process, possibly by inhibition of IL-8 production, in TNB-induced colitis in rats both in vivo and in vitro. These findings may have potentially important implications for the therapeutic use of berberine in IBD, in part by disrupting the cycle of cellular mediators.

Acknowledgments
We thank Prof. K. Ohya, Prof. S. Kasugai, and Dr. H. Kondo from the Department of Denial Pharmacology, Dr. T. Kuroiwa and T. Tajima from the Department of Neuropathology, and Asst. Prof. K.
References


Send reprint requests to: Dr. Satoru Mineshita, Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-Ku, Tokyo 113-8510, Japan. E-mail: satoru-mineshita.prm@mi.tmd.ac.jp